Company news
Curanex Pharmaceuticals Inc (NASDAQ:CURX) news
Curanex Pharmaceuticals Inc news releases on 6ix. Latest, Apr 2, 2026: Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing…
Press releases & updates
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company
April 1, 2026
Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission
March 29, 2026
Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission
March 17, 2026
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
March 11, 2026
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
March 10, 2026
Curanex Forms World Class Scientific Advisory Board
March 4, 2026
Curanex Provides Operational Update on Key Regulatory Milestones
February 24, 2026
Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement
October 22, 2025
Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters
September 12, 2025
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering
August 27, 2025
Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
August 26, 2025